I-131-Apamistamab for acute myeloid leukaemia

I-131-Apamistamab is in clinical development for the treatment of adult patients with relapsed, or refractory acute myeloid leukaemia (AML), prior to bone marrow transplant. AML is a type of blood cancer where excess immature white blood cells are made by the bone marrow, these immature cells do not function like healthy blood cells in fighting off infections or carrying oxygen around the body, which causes the symptoms of AML. It is an acute cancer which means it progresses quickly and aggressively, needing immediate treatment, and is most common in people aged 60 years and over.